Vertex Reports First-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Vertex (VRTX) PT Raised to $125 at Credit Suisse; Raise Probability of Triplet to 75%
April 28, 2017 6:26 AM EDTCredit Suisse raised its price target on Vertex (NASDAQ: VRTX) to $125.00 (from $108.00) while maintaining a Outperform rating.
Analyst Alethia Young raised their probability of success to 75% from 50% to the triplet in the HetMin population. They model $2.1B in peak sales in HetMin.
... MoreVertex Pharma (VRTX) Tops Q1 EPS by 1c
April 27, 2017 4:18 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $0.41, $0.01 better than the analyst estimate of $0.40. Revenue for the quarter came in at $481 million versus the consensus estimate of $510.6 million.
"During the quarter, our progress toward treating more people with CF was marked by several important milestones, including expanding the number of people being treated with our approved medicines and developing potential new medicines to treat all people with CF in the future," said Jeffrey Leiden, M.D., Ph.D., Chairman,... More
